Analyzing Boston Scientific's Fundamental Performance Before Investing

By Emilio Sanchez • Sunday, June 29 10:00 • Permanent Link

More and more people are talking about Boston Scientific over the last few weeks. Is it worth buying the Medical Instruments & Supplies stock at a price of $106.53? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Boston Scientific has moved 39.4% over the last year, and the S&P 500 logged a change of 12.7%
BSX has an average analyst rating of buy and is -9.37% away from its mean target price of $117.55 per share
Its trailing earnings per share (EPS) is $1.37
Boston Scientific has a trailing 12 month Price to Earnings (P/E) ratio of 77.8 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $2.79 and its forward P/E ratio is 38.2
The company has a Price to Book (P/B) ratio of 7.09 in contrast to the S&P 500's average ratio of 4.74
Boston Scientific is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
BSX has reported YOY quarterly earnings growth of 36.4% and gross profit margins of 0.7%
The company has a free cash flow of $2.32 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.